Results 71 to 80 of about 41,454 (219)
Recent updates on correlates of vaccine-induced protection
Frontiers in Immunology, 2023 Correlates of protection are key for vaccine development against any pathogen. In this paper we summarize recent information about correlates for vaccines against dengue, Ebola, influenza, pneumococcal, respiratory syncytial virus, rotavirus, shigella ...
Stanley A. Plotkin, Stanley A. Plotkin
doaj +1 more source
Health Diplomacy in Africa: Prospects, Obstacles, and the Way Ahead
Public Health Challenges, Volume 5, Issue 2, June 2026.ABSTRACT Introduction Africa faces a complex and evolving health landscape marked by endemic diseases, emerging infectious threats, fragile health systems, climate change, and geopolitical pressures. In this context, health diplomacy has become an important mechanism for fostering collaboration, mobilizing resources, and advancing collective health ...
Majani Edward
wiley +1 more source
Uirusu, 2015 Filoviruses (Ebola and Marburg viruses) cause severe hemorrhagic fever in humans and nonhuman primates. No effective prophylaxis or treatment for filovirus diseases is yet commercially available. The recent outbreak of Ebola virus disease in West Africa has accelerated efforts to develop anti-Ebola virus prophylaxis and treatment, and unapproved drugs ...
openaire +3 more sources
Cell, 2020 Ervebo is the first licensed vaccine for prevention of Ebola virus disease. The vaccine, originally developed by the Public Health Agency of Canada, is delivered in a single 1 mL dose and has been delivered to >200,000 people in an ongoing 2018-2020 outbreak of disease. To view this Bench to Bedside, open or download the PDF.
openaire +2 more sources
Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay. [PDF]
, 2011 Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide.
Agudelo, Juliet +10 more
core +1 more source
F1000Research, 2015 The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD).
Veljko Veljkovic +7 more
doaj +1 more source
Infectious Disease Response in Tanzania: Enhanced Strategies From the 2023 to 2025 Marburg Outbreaks
Public Health Challenges, Volume 5, Issue 2, June 2026.ABSTRACT The 2023 Marburg virus disease (MVD) outbreak in Tanzania, which resulted in nine confirmed cases and six deaths (case fatality rate [CFR]: 66.7%), served as a critical stress test of the national health system, revealing significant gaps in outbreak preparedness across surveillance, laboratory capacity, and infection prevention and control ...
Huda Haque +6 more
wiley +1 more source
Global Health Security in an Era of Explosive Pandemic Potential [PDF]
, 2017 Pandemics pose a significant risk to security, economic stability, and development. Annualized expected losses from pandemics are estimated at $60 billion per year. Despite the certainty and magnitude of the threat, the global community has significantly
Ayala, Ana, Gostin, Lawrence O.
core +1 more source
Estimating the reproduction number of Ebola virus (EBOV) during the 2014 outbreak in West Africa [PDF]
, 2014 The 2014 Ebola virus (EBOV) outbreak in West Africa is the largest outbreak of the genus Ebolavirus to date. To better understand the spread of infection in the affected countries, it is crucial to know the number of secondary cases generated by an ...
Althaus, Christian L.
core +2 more sources
Identifying and Quantifying Conflicts Between Humans and Terrestrial Mammals in Great Britain
Mammal Review, Volume 56, Issue 2, June 2026.We conducted a literature review to identify conflicts between humans and terrestrial mammals in Great Britain. A modified Generic Impact Scoring System was applied to all conflicts so that mammals could be ranked according to their level of impact to help identify the most damaging species and to aid decision‐making. ABSTRACT Introduction Interactions
Kate L. Palphramand +3 more
wiley +1 more source